Mirum Pharmaceuticals

Yahoo Finance • last year

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments • Mirum has acquired Travere’s rights and assets related to Cholbam® and Chenodal® • Advances Travere’s strategy... Full story

Yahoo Finance • last year

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., June 10, 2023--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 9, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qual... Full story

Yahoo Finance • 2 years ago

Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors

FOSTER CITY, Calif., December 19, 2022--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nomina... Full story